Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial

[1]  D. Ardissino,et al.  Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis , 2010, Circulation.

[2]  Martin Möckel,et al.  Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. , 2010, Journal of the American College of Cardiology.

[3]  C. Terkelsen,et al.  Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. , 2010, Journal of the American College of Cardiology.

[4]  D. Atsma,et al.  Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). , 2010, The American journal of cardiology.

[5]  S. Pocock,et al.  A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.

[6]  Gregg W Stone,et al.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.

[7]  C. Sosnowski.  [Commentary to the article: Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus- -eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet, 2010; 375: 201-209]. , 2010, Kardiologia polska.

[8]  J. Rassen,et al.  Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. , 2010, European heart journal.

[9]  M. Nazzaro,et al.  Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. , 2010, Journal of the American College of Cardiology.

[10]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[11]  D. Mozaffarian,et al.  Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[12]  P. Smits,et al.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.

[13]  S. Pocock,et al.  Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial , 2010, Circulation.

[14]  B. Gersh,et al.  Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. , 2009, The New England journal of medicine.

[15]  J. Ornato,et al.  2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[16]  J. Hartikainen,et al.  Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries , 2009, European heart journal.

[17]  B. Gersh,et al.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial , 2009, The Lancet.

[18]  G. De Luca,et al.  Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial. , 2009, Circulation.

[19]  George Dangas,et al.  Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. , 2009, Journal of the American College of Cardiology.

[20]  E. Antman,et al.  Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial , 2009, The Lancet.

[21]  Michael Weis,et al.  Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.

[22]  Sunil V. Rao,et al.  Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients With In-Hospital Bleeding , 2008, Circulation.

[23]  Aloke V. Finn,et al.  Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study , 2008, Circulation.

[24]  Deepak L. Bhatt,et al.  The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. , 2008, American heart journal.

[25]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[26]  G. Stone,et al.  Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. , 2008, International journal of cardiology.

[27]  F. Prati,et al.  Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. , 2008, JAMA.

[28]  J. Ottervanger,et al.  Comparison between stenting and balloon in elderly patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. , 2007, International journal of cardiology.

[29]  K. Eagle,et al.  Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.

[30]  H. Dauerman,et al.  Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction , 2007, Coronary artery disease.

[31]  C. Grines,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Journal of the American College of Cardiology.

[32]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[33]  Harlan M. Krumholz,et al.  Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry , 2006, Circulation.

[34]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[35]  Sunil V. Rao,et al.  Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions , 2006, Journal of Thrombosis and Thrombolysis.

[36]  A. Investigators.  Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. , 2005, European heart journal.

[37]  Sunil V. Rao,et al.  Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.

[38]  A. Kastrati,et al.  Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting. , 2004, European heart journal.

[39]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials , 2003, The Lancet.

[40]  A. Biedler,et al.  Impact of Alloantigens and Storage-associated Factors on Stimulated Cytokine Response in an In Vitro Model of Blood Transfusion , 2002, Anesthesiology.

[41]  J. J. Griffin,et al.  Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. , 2002, The New England journal of medicine.

[42]  J. Maessen,et al.  Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. , 1999, Chest.

[43]  J. Tijssen,et al.  5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Ele , 2011, JACC. Cardiovascular interventions.

[44]  E. Bramucci,et al.  Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). , 2011, JACC. Cardiovascular interventions.

[45]  W. Howland,et al.  Hemodynamic oxygen transport and 2,3-diphosphoglycerate changes after transfusion of patients in acute respiratory failure , 2004, Intensive Care Medicine.

[46]  E. Moore,et al.  Stored red blood cells selectively activate human neutrophils to release IL-8 and secretory PLA2. , 2000, Shock.

[47]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .